Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
EGFR-TKI has firmly established itself as a first-line treatment for advanced lung cancer with EGFR-sensitive mutations, and the ADAURA study has added to its indications for use as postoperative adjuvant therapy in early- and mid-stage lung cancer.However, clinical data on neoadjuvant EGFR-TKI therapy are still incomplete. A phase II clinical study, CTONG1103, currently ongoing, comparing the efficacy of the first generational EGFR-TKI erlotinib and gemcitabine combined with cisplatin as neoadjuvant therapy for stage IIIA-N2 EGFR mutation-positive non-small-cell lung cancer, did not yield significantly positive objective remission rate (ORR) results. Furmonertinib is a third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations.Furmonertinib demonstrates definite efficacy and favorable safety in first-line EGFR-sensitive mutations and EGFR T790M Mutations in second-line and late-line treatment of advanced NSCLC.The aim of this study was to explore the efficacy and safety of furmonertinib neoadjuvant therapy for resectable stage II-IIIB EGFR-sensitive mutant non-small cell lung cancer efficacy and safety. Patinents are planned to be recruited from five centers in China. Eligible patients will receive furmonertinib neoadjuvant therapy for 8 weeks to evaluate the efficacy and safety of furmonnertinib neoadjuvant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzony rak płuca (biopsia lub cytologia) w ciągu ostatnich 60 dni
- •Stadium II-IIIB raka płuca możliwe do usunięcia chirurgicznie
- •Obecność mutacji EGFR (delecja egzonu 19 lub mutacja L858R w egzonie 21)
- •Co najmniej jeden widoczny guz o rozmiarze minimum 10 mm
- •Brak wcześniejszego leczenia przeciwnowotworowego
- •Prawidłowa funkcja nerek, wątroby i krwi
- •Zgoda na stosowanie skutecznej antykoncepcji/brak ciąży
✗ Disqualifies
- •Wcześniejsze leczenie przeciwnowotworowe
- •Wiele guzów pierwotnych płuca jednocześnie
- •Historia innych nowotworów (chyba że całkowicie usunięte 5+ lat temu)
- •Historia choroby śródmiąższowej płuc
- •Poważne problemy z połykaniem lub przywłaszczaniem leków
- •Nieuleczona nadciśnienie, cukrzyca, zawał lub aktywna infekcja HIV/HBV/HCV
- •Stosowanie silnych leków wchodzących w interakcje (w ciągu 7-21 dni przed badaniem)
- •Inne ciężkie lub niekontrolowane choroby ogólnoustrojowe
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
180 Fenglin Road
Shanghai, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.